Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Go back to Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 246.51 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $246.51 | 52 Week High | $109.10 | |||
| Open | $246.51 | 52 Week Low | $31.38 | |||
| Day High | $246.51 | P/E | N/A | |||
| Day Low | $246.51 | EPS | $-1.45 | |||
| Volume | 263 | |||||
